A new intranasal DNA vaccine for tuberculosis, developed by researchers at Johns Hopkins University, has shown promising results in animal trials. When administered to mice alongside first-line TB drugs, the vaccine helped clear bacteria faster, reduced lung inflammation, and prevented relapse after treatment ended. The vaccine targets drug-tolerant TB "persisters" by combining two genes, relMtb and Mip3ฮฑ, to stimulate immune responses in the lungs and throughout the body. It boosted dendritic cell activity and strengthened interactions with CD4 and CD8 T cells, creating durable immunity. In rhesus macaques, the vaccine triggered measurable TB-specific immune responses in both blood and airways, lasting at least six months. Study lead Styliani Karanika, assistant professor at Johns Hopkins University School of Medicine, said the vaccine enhanced the effectiveness of the drug combination bedaquiline, pretomanid, and linezolid. The findings were published in the Journal of Clinical Investigation. According to the World Health Organisation, about 2 billion people globally have latent TB, with over 10 million developing active disease in 2024, leading to 1.2 million deaths.
The most striking aspect of this development is not just the vaccine's efficacy in animals, but that it directly challenges the long-standing reliance on prolonged antibiotic regimensโa weak point in TB control that has fueled drug resistance and treatment fatigue. Styliani Karanika's work at Johns Hopkins targets the very mechanism that allows TB to linger and rebound, suggesting a shift from purely antimicrobial strategies to ones that actively engage the immune system.
This approach arrives at a critical time, given that TB remains the world's deadliest infectious disease, with 1.2 million deaths in 2024 alone. The fact that the vaccine enhances the potency of existing drug combinations, including those for drug-resistant TB, signals a potential multiplier effect in treatment outcomes. For regions burdened by high TB prevalence and strained healthcare systems, such a tool could reduce treatment duration and improve completion rates.
For millions living with latent or active TB, particularly in low-resource settings, a durable, easy-to-administer vaccine could transform disease managementโthough access will depend on whether this technology moves swiftly into human trials and affordable production. While the study is still in preclinical stages, the durability of immune response and nasal delivery method suggest a practical advantage over injectable or short-acting alternatives.
This innovation fits into a broader global shift toward immunotherapeutic solutions for chronic infections, moving beyond antibiotics as the sole frontline defense.
💡 NaijaBuzz is an AI-assisted news aggregator. This content is curated from third-party sources โ NaijaBuzz is not the original publisher and is not responsible for the accuracy of source reporting. The NaijaBuzz Take is AI-assisted editorial opinion only, not established fact. All persons mentioned are presumed innocent until proven guilty by a court of competent jurisdiction. NaijaBuzz does not endorse the views expressed in source articles.
